Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of the Safety and Effectiveness of a Single Oral Dose of NXN 188 for the Treatment of Moderate to Severe Migraine Headache With Aura

NCT00920686 is registered in ClinicalTrials.gov with NeurAxon Inc. as lead sponsor.

NCT NCT00920686
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00920686 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of the Safety and Effectiveness of a Single Oral Dose of NXN 188 for the Treatment of Moderate to Severe Migraine Headache With Aura
Lead sponsor
NeurAxon Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2009
Completion date
March 31, 2010
Enrollment
239 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

migraine with aura